Mylan (NASDAQ:MYL) – Equities research analysts at Leerink Swann issued their Q1 2018 earnings per share (EPS) estimates for Mylan in a note issued to investors on Tuesday. Leerink Swann analyst A. Fadia anticipates that the company will post earnings per share of $1.09 for the quarter. Leerink Swann has a “Market Perform” rating and a $44.00 price target on the stock. Leerink Swann also issued estimates for Mylan’s Q2 2018 earnings at $1.29 EPS, Q3 2018 earnings at $1.41 EPS, Q4 2018 earnings at $1.56 EPS and FY2022 earnings at $7.84 EPS.

Several other research firms also recently weighed in on MYL. Citigroup restated a “buy” rating and issued a $58.00 price target (up previously from $48.00) on shares of Mylan in a research note on Thursday. Cantor Fitzgerald set a $41.00 price target on Mylan and gave the stock a “hold” rating in a research note on Tuesday, December 26th. BidaskClub upgraded Mylan from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, December 19th. Guggenheim began coverage on Mylan in a research note on Tuesday, December 12th. They issued a “buy” rating and a $59.00 price target on the stock. Finally, Mizuho restated a “buy” rating and issued a $37.00 price target on shares of Mylan in a research note on Tuesday, October 24th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $43.20.

Shares of Mylan (MYL) opened at $44.54 on Thursday. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.46 and a quick ratio of 0.95. The firm has a market capitalization of $23,770.00, a P/E ratio of 26.83, a P/E/G ratio of 2.78 and a beta of 1.38. Mylan has a 52 week low of $29.39 and a 52 week high of $45.87.

Mylan (NASDAQ:MYL) last posted its quarterly earnings results on Monday, November 6th. The company reported $1.10 earnings per share for the quarter, missing the consensus estimate of $1.20 by ($0.10). The company had revenue of $2.99 billion during the quarter, compared to analysts’ expectations of $3.09 billion. Mylan had a return on equity of 20.63% and a net margin of 7.28%. The business’s quarterly revenue was down 2.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.38 EPS.

A number of institutional investors and hedge funds have recently modified their holdings of the business. Greenlight Capital Inc. boosted its stake in shares of Mylan by 0.4% in the 3rd quarter. Greenlight Capital Inc. now owns 10,744,307 shares of the company’s stock worth $337,048,000 after buying an additional 42,600 shares during the last quarter. Wealthsource Partners LLC boosted its stake in shares of Mylan by 57.6% in the 3rd quarter. Wealthsource Partners LLC now owns 14,705 shares of the company’s stock worth $461,000 after buying an additional 5,375 shares during the last quarter. Americafirst Capital Management LLC purchased a new position in shares of Mylan in the 3rd quarter worth $471,000. Cypress Capital Group boosted its stake in shares of Mylan by 37.7% in the 3rd quarter. Cypress Capital Group now owns 13,079 shares of the company’s stock worth $410,000 after buying an additional 3,579 shares during the last quarter. Finally, California Public Employees Retirement System boosted its stake in shares of Mylan by 4.2% in the 3rd quarter. California Public Employees Retirement System now owns 1,129,978 shares of the company’s stock worth $35,447,000 after buying an additional 45,822 shares during the last quarter. Institutional investors and hedge funds own 74.90% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece was originally posted by Watch List News and is the property of of Watch List News. If you are viewing this piece on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright legislation. The correct version of this piece can be accessed at https://www.watchlistnews.com/equities-analysts-issue-forecasts-for-mylans-q1-2018-earnings-myl/1797107.html.

About Mylan

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with Analyst Ratings Network's FREE daily email newsletter.